Fulltext

Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients

Soon SS 1 , Chia WK 2 , Chan ML 1 , Ho GF 3 , Jian X 4 , Deng YH 4 Show all authors , Tan CS 5 , Sharma A 6 , Segelov E 7 , Mehta S 8 , Ali R 9 , Toh HC 2 , Wee HL 1

Affiliations 

  • 1 Department of Pharmacy, National University of Singapore, Singapore, Singapore
  • 2 Department of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
  • 3 Department of Radiation Oncology, University of Malaya Medical Centre, Kuala Lumpur, Malaysia
  • 4 Department of Medical Oncology, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
  • 5 Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
  • 6 Department of Oncology, All India Institute of Medical Sciences, New Delhi, India
  • 7 National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia
  • 8 Department of Digestive Diseases and Nutrition, Tata Memorial Hospital, Mumbai, India
  • 9 Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
PLoS One, 2014;9(9):e107866.
PMID: 25250815 DOI: 10.1371/journal.pone.0107866

Abstract

Recent observational studies showed that post-operative aspirin use reduces cancer relapse and death in the earliest stages of colorectal cancer. We sought to evaluate the cost-effectiveness of aspirin as an adjuvant therapy in Stage I and II colorectal cancer patients aged 65 years and older.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications